Fiblast (Trafermin) in acute stroke: Results of the european-australian phase II/III safety and efficacy trial

Cerebrovascular Diseases

Volumn 14, Issue 3-4, 2002, Pages 239-251

  Bogousslavsky, Julien ^a   Victor, Stephen Jay ^b,i   Salinas, Eliseo O ^b   Pallay, Allan ^b   Donnan, Geoffrey A ^c   Fieschi, Cesare ^d   Kaste, Markku ^e   Orgogozo, Jean Marc ^f   Chamorro, Angel ^g   Desmet, Anne ^h  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f HÔPITAL PELLEGRIN   (France)

^g HOSPITAL CLÍNIC   (Spain)

^h Clinical Research and Development   (France)

ⁱ Clinical Research   (France)

Author keywords

Acute stroke; Basic fibroblast growth factor; Fiblast (trafermin); Neuroprotection; Recovery

Indexed keywords

PLACEBO; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR;

ADULT; ANALYSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROPROTECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STROKE; SYMPTOM; SYSTOLIC BLOOD PRESSURE;

CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FIBROBLAST GROWTH FACTORS; HUMANS; INFUSIONS, INTRAVENOUS; PEPTIDE FRAGMENTS; SAFETY;

EID: 0036968150     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065683     Document Type: Article

References (34)

1. Brott T, Bogousslavsky J: Treatment of acute ischemic stroke. N Engl J Med 2000;343:710-722.
2. Sherman DG: Heparin and heparinoids in stroke. Neurology 1998;51(3 suppl):S56-S58.
3. Counsell C, Sandercock P: Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev 2000;2: CD000119.
4. Marler JR, Brott T, Broderick J, Kothari R, O'Donoghue M, Barsan W, Tomsick T, Spilker J, Miller R, Sauerbeck L, Farrell J, Kelly J, Per-kins T, McDonald T, Rorick M, Hickey C, Armitage J, Perry C, Thalinger K, et al: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
5. Wardlaw JM, del Zoppo G, Yamaguchi T: Thromolysis for acute ischaemic stroke. Coch-rane Database Syst Rev 2000;2:CD000213.
6. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE: Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. JAMA 2000;283:2395-2403.
7. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F: Intraarterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. JAMA 1999;282:2003-2011.
8. Devuyst G, Bogousslavsky J: Recent progress in drug treatment for acute stroke. J Neurol Neurosurg Psychiatry 1999;67:420-425.
9. Lees KR: Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49(5 suppl 4):S66-S69.
10. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J: Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial. Lancet 2000;355:1949-1954.
11. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T: Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 2000;31:2543-2551.
12. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE: A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30: 2592-2597.
13. Bath PMW, Blecic S, Bogousslavsky J, Boysen G, Davis S, Diez-Tejedor E, Ferro JM, Gommans J, Hacke W, Indredavik B, Norrving B, Orgogozo JM, Ringelstein EB, Sacchetti ML, Iddenden R, Bath FJ, Musch BC, Brosse DM, Naberhuis-Stehouwer SA: Tirilazad mesylate in acute ischemic stroke: A systematic review. Stroke 2000;31:2257-2265.
14. DeGraba TJ: The role of inflammation after acute stroke: Utility of pursuing anti-adhesion molecule therapy. Neurology 1998;51(3 suppl 3):S62-S68.
15. Wahlgren NG, Ranasinha KW, Rosolacci T, Franke CL, van Erven PM, Ashwood T, Claesson L: Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1,360 acute stroke patients. Stroke 1999;30:21-28.
16. Lin DA, Finklestein SP: Basic fibroblast growth factor: A treatment for stroke? Neuroscientist 1997;3:247-250.
17. Fisher M, Meadows ME, Do T, Charette M, Finklestein SP: Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1995;15:953-959.
18. Ren JM, Finklestein SP: Time window of infarct reduction by intravenous basis fibroblast growth factor in focal cerebral ischemia. Eur J Pharmacol 1997;327:11-16.
19. Jiang N, Finklestein SP, Do T, Caday CG, Charette M, Chopp M: Delayed intravenous administration of basic fibroblast growth factor (bFGF) induces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat. J Neurol Sci 1996;139:173-179.
20. Bethel A, Kirsch JR, Koehler RC, Finklestein SP, Traystman RJ: Intravenous basic fibroblast growth factor decreases brain injury resulting from focal ischemia in cats. Stroke 1997;28: 609-615.
21. Huang Z, Chen K, Huang PL, Finklestein SP, Moskowitz MA: bFGF ameliorates focal ischemic injury by blood flow-independent mechanisms in eNOS mutant mice. Am J Physiol 1997;272:H1401-H1405.
22. Kawamata T, Dietrich WD, Schallert T, Gotts JE, Cocke RR, Benowitz LI, Finklestein SP: Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci USA 1997;94:8179-8184.
23. Kawamata T, Ren JM, Cha JH, Finklestein SP: Intracisternal antisense oligonucleotide to growth associated protein-43 blocks the recovery-promoting effects of basic fibroblast growth factor after acute stroke. Exp Neurol 1999;158: 89-96.
24. The Fiblast Safety Study Group: Clinical safety trial of intravenous basic fibroblast growth factor (bFGF, FIBLAST) in acute stroke (abstract). Stroke 1998;29:287.
25. Clark WM, Schim JD, Kasner SE, Victor S: Trafermin in acute ischemic stroke. Results of a phase II/III randomized efficacy study (abstract). Neurology 2000;54:A88.
26. Goldstein LB, Bartels C, Davis JN: Interrater reliability of the NIH Stroke Scale. Arch Neurol 1989;46:660-662.
27. Rankin J: Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scott Med J 1957;2:200-215.
28. Mahoney FI, Barthel DW: Functional evaluation: The Barthel Index. Md State Med J 1965; 14:61-65.
29. McCullagh P: Regression models for ordinal data (with discussion). J R Stat Soc 1980;B42: 109-142.
30. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526.
31. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
32. Chamorro A, Vila N, Ascase C, Elices E, Schonewille W, Blanc R: Blood pressure and functional recovery in acute ischemic stroke. Stroke 1998;29:1850-1853.
33. Akins PT, Liu PK, Hsu CY: Immediate early gene expression in response to cerebral ischemia. Friend or foe? Stroke 1996;27:1682-1687.
34. Tao Y, Black IB, DiCicco-Bloom E: Neurogenesis in neonatal rat brain is regulated by peripheral injection of basic fibroblast growth factor (bFGF). J Comp Neurol 1996;376:653-663.